Jump to a particular year :

  • All
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014

News & Events

4P-Pharma joins forces with Qingdao Marine Biomedical Research Institute for translation research in China and Europe

4P-Pharma and Qingdao Marine Biomedical Research Institute (QMBRI) have decided to combine their expertise to jointly develop their first-in-class drug candidates in China and Europe through the signature of a Memorandum of Understanding (MoU) to deal with their respective molecules.

 

“[…] It is our ambition to create a fruitful and long-term partnership for our two countries and patients worldwide”, said Dali Zhang, Vice-President of QMBRI.

 

“We are very pleased to build this partnership with QMBRI’s team. […]”, said Revital Rattenbach, Chairwoman of 4P-Pharma and 4Moving Biotech. “We strongly believe that our combining work will definitely benefit to Chinese, European and worldwide patients.”

 

“[…] I am especially happy of QMBRI and 4P-Pharma’s partnership”, said Mr. Daowen Du, European director of ICCIC-Gung Ho. “The possibility to provide a quick access of repositioning drugs, whose benefit/risk ratio has been positively proved, to the largest number of people is particularly important for China. We welcome very strongly 4P-Pharma’s expertise to guarantee Chinese drug candidates’ arrival in Europe.”

 

 

Read the full press release:
EN: 20210916_PR_MOU_QMBRI_EN

FR: 20210916_PR_MOU_QMBRI_FR

Press contact 4P-Pharma
Roselina Lam, Business Development and Licensing Manager
E-mail: roselina@4p-pharma.com

4Moving Biotech at EULAR 2021

Pr. Francis Berenbaum, 4Moving Biotech’s CEO and CMO, Head of Rheumatology department at Saint-Antoine Hospital (AP-HP), will present a poster entitled « Liraglutide Has Potent Anti-inflammatory And Anti-catabolic Activity In Two Cell Types Implicated In Osteoarthritis » (# POS0373) on our recent results on 4P004 during the European congress of rheumatology (EULAR) 2021 virtual congress that will take place on June 2-5, 2021.

For further information, please click on the following link  : https://congress.eular.org/index.cfm

 

4P-Pharma at BIO Digital 2021

4P-Pharma will attend the upcoming BIO International Convention held virtually as BIO Digital, on June 10-11 & 14-18, 2021, as part of the Business France virtual French pavilion.

Contact Roselina Lam, our Business Development and Licensing Manager, via the partnering platform or by e-mail, to learn more about us and discuss future partnerships.

She is looking forward to meet you there!

For further information: https://www.bio.org/events/bio-digital

The OA-BIO European Consortium, led by 4Moving Biotech, awarded a Eurostars grant to develop 4P004 through a biomarkers-driven approach

4Moving Biotech (France), Utrecht University (The Netherlands), Chondrometrics GmbH (Germany) and AO Research Institute Davos (Switzerland) have received a EUREKA-Eurostars grant award to finance its €4,2M project (OA-BIO) to complete early clinical development (Phase I) of 4P004, a first-in-class disease modifying osteoarthritis drug (DMOAD), and to identify and validate OA imaging and liquid biopsy biomarkers.

“OA-BIO Eurostars grant represents a unique opportunity to bring together some of the most renowned European teams in the field of OA biomarkers […]”, said Prof. Francis Berenbaum, CEO/CMO of 4Moving Biotech, Head of rheumatology department at Saint-Antoine Hospital (AP-HP), Professor at Sorbonne University (Paris, France) and Director of the INSERM UMR-S938 research.

 

“OA-BIO […] will advance our understanding on OA biomarkers across the species that typically suffer from OA, like horses and dogs […]”, added Prof. Marianna Tryfonidou, Professor of Regenerative Orthopedics at Faculty of Veterinary Medicine of Utrecht University.

 

“[…] OA-BIO has a large potential to promote the understanding of the disease and to make a step towards urgently needed therapies”, completed Prof. Felix Eckstein, CEO/CMO of Chondrometrics.

 

“The OA-BIO consortium breakthrough lies in correlating OA imaging biomarkers with OA molecular ones, […] , as well as to follow how the innovative 4P004 treatment will efficiently interfere with the progression of the OA disease. […]”, concluded Prof. Mauro Alini, Vice-Director of ARI.

Read the full press release:
EN: 20210520_PR_4Mov_Eurostars_vEN
FR: 20210520_PR_4Mov_Eurostars_vFR

Press contact 4Moving Biotech
Roselina Lam, Business Development and Licensing Manager
E-mail: contact@4moving-biotech.com

4Moving Biotech announces a closing of €2M investment to implement 4P004 phase 1 clinical trial on Osteoarthritis patients

4Moving Biotech, announces that it has closed a €2M investment agreement with 4P- Pharma, SATT Lutech, French Tech Seed and business angels. 4Moving Biotech is the spin-off of 4P-Pharma focusing on the development of 4P004, a first-in-class Disease Modifying OsteoArthritis Drug (DMOAD). 4Moving Biotech intends to use the proceeds to initiate a phase I clinical trial on people suffering from osteoarthritis.

“The incorporation and development of 4Moving Biotech is the proof of the relevancy of 4P-Pharma business model: bringing to patient the best innovations from academic scientists, in a relatively short time and with limited risks. […]”, says Revital Rattenbach, Chairwoman of 4Moving Biotech and 4P-Pharma.

 

“This fundraising gives us an extraordinary opportunity to conduct our first clinical trial in women and men suffering from OA with 4P004. […]”, adds Francis Berenbaum, CEO/CMO of 4Moving Biotech, Head of rheumatology department at Saint-Antoine Hospital (AP-HP), and Professor at Sorbonne University (Paris, France).

Read the full press release:
EN: 20210429_PR_4Mov_Closing_vEN
FR: 20210429_PR_4Mov_Financement_FR

Press contact 4Moving Biotech
Roselina Lam, Business Development and Licensing Manager
E-mail: contact@4moving-biotech.com